OP/ED-Biosimilar Drugs Require More Transparent Communication Between Patient and Pharmacist: SB 5935 Needs Work
Very recently during the 64th Legislature in the State of Washington, House Bill 1675 was introduced relating to the prescription of biological products and interchangeable biological products. The bill addressed the process through which a biosimilar that has been given ‘interchangeable’ status by the FDA can be substituted for the innovator biologic it mimics.
You and your doctor decide you need surgery. As you are lying on the operating room (O.R.) table looking up at the ‘many faces behind the masks,’ do you ask yourself, “did everyone here graduate from an accredited program before being hired?” As a healthcare consumer, chances are that you expect all healthcare professionals, regardless
A formal complaint submitted to the Department of Health and Human Services in May 2014 contended that Florida insurers offering plans through the new federal marketplace (exchange) had structured their drug formularies to discourage people with human immunodeficiency virus infection from selecting their plans.